Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current


Recap: Biohaven Pharma Hldgs Q2 Earnings

Author: Benzinga Insights | August 05, 2022 05:40pm

Biohaven Pharma Hldgs (NYSE:BHVN) reported its Q2 earnings results on Friday, August 5, 2022 at 07:00 AM.

Here's what investors need to know about the announcement.


Biohaven Pharma Hldgs missed estimated earnings by 48.06%, reporting an EPS of $-3.82 versus an estimate of $-2.58.

Revenue was up $122.15 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.91 which was followed by a 0.56% increase in the share price the next day.

Here's a look at Biohaven Pharma Hldgs's past performance:

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate -2.53 -2.04 -2.40 -2.74
EPS Actual -1.62 -2.32 -1.91 -2.62
Revenue Estimate 181.11M 173.69M 128.40M 78.13M
Revenue Actual 318.85M 190.01M 135.74M 92.93M

To track all earnings releases for Biohaven Pharma Hldgs visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Posted In: BHVN